Clinical Trial Update: Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. [Phase 2]

View source ↗

Summary

Phase 2 trial of Orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors was terminated. No efficacy results are provided in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulosa Cell Tumor of the Ovary

Drugs mentioned

• Orteronel (TAK-700) (Orteronel)

Snippet

Sponsor: Grupo Español de Tumores Huérfanos e Infrecuentes | Conditions: Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | Phase 2 | Status: TERMINATED